Markus Aebi is a professor at ETH Zürich and has worked on various aspects of glycobiology in prokaryotic and eukaryotic microorganisms. His laboratory uses microbial model systems to study mechanistic and functional aspects of glycans. He has made several key contributions to the dissection of the eukaryotic pathway of N-linked protein glycosylation in the yeast Saccharomyces cerevisiae. His laboratory continues to work on the molecular mechanism of N-linked protein glycosylation in bacterial (classical and non-classical) and eukaryotic cells as well as the processing of N-linked glycans in the ER and the Golgi.
Michael J. Betenbaugh
Michael Betenbaugh is a professor in the field of cellular engineering of eukaryotes at the John Hopkins University. His work is focusing on enhancing the quality of recombinant proteins, vaccines, cells and metabolites. His lab is covering both modelling and experimental frameworks of glycoengineering to achieve high value products for industry.
Nico Callewaert is a director of the VIB Center for Medical Biotechnology Center at Ghent University. His lab is focusing on innovative biotechnological tools for glycobiological and biological systems engineering to improve diagnostics and to prevent and treat disease. Current projects are in tuberculosis vaccine engineering, molecular diagnostics and biopharmaceutical glycoprotein engineering.
Michael Butler has recently been appointed as Chief Scientific Officer (CSO) at the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. Prof Butler is an acknowledged global leader in mammalian cell culture bioprocessing. His research career has seen key advances in animal cell technology, glycosylation, and development of mammalian cell culture bioprocesses for scale-up and industrial production. He also has a strong record of leading industry-academic collaborations.
Hendrik Clausen is the Head of the Copenhagen Center for Glycomics. He and his group take a genetic approach to explore and map the function of glycans. Gene editing via CRISPR/Cas9, Zinc finger Nucleases and TALENs is applied to interrogate the structure and function of glycogenes, and to precisely engineer cells with specific glycosylation capacities. By deconstructing, assigning and manipulating the glycosylation machinery in mammalian cells, his group aims to understand how glycans influence the biology of cells during tissue formation, inflammation, immunity and cancer growth, and how this can be exploited for early detection and treatment of diseases.
Dietmar Reusch is the director of the Development Characterization Analytics department at Hoffmann- La Roche AG. His group is responsible for the extended characterization of all large molecules in the clinics from Phase I and marketed products, including glycoanalysis and mass spectrometry. He has contributed to establishing high-throughput methods for the glycoanalysis of IgG.